Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.

Biotechnology

Kura Oncology

Troy Wilson 

Kate McElhone

Roger Bakale

Tanya Spektor

Michael Grieco

Matt Kelly

Jianbing Zhang

Hunkar Gunes

Harris S. Soifer

David Reed

Daniel Corum

Arlette Holland

Kelly Cannan- Kennerly

Brian Powl

Maureen Clancy

Peter Dorff

Kathleen Ford

Mollie Leoni

Stephen Dale

Tom Doyle

Pete De Spain

Teresa Bair

Francis Burrows

The Leadership Team at Kura Oncology is responsible for guiding the company's strategic direction and operational execution, focusing on advancing precision medicine in cancer treatment. Comprising experts in clinical development, regulatory affairs, finance, and commercial strategy, this team collaborates to drive innovative drug discovery, ensure compliance with regulatory standards, and effectively communicate with investors and the public, ultimately working to improve patient outcomes through targeted therapies.

Leadership Team

Clinical Research and Development

Finance and Accounting

Leadership Team

About

Team members

Other teams at Kura Oncology

Clinical Research and Development

Finance and Accounting